Monday, July 4, 2016

Insulin Potentiation Therapy (IPT)

Donato Perez Garcia
Hospital Angeles Tijuana

Insulin Potentiation Therapy (IPT) was invented in 1930 by a surgeon lieutenant of the Mexican military, Dr. Donato Pérez García, Sr. (1896-1971), as a remedy for chronic degenerative diseases. Insulin was first isolated from pancreatic tissue in Canada and used as a treatment for diabetes in early 1920’s, years later in Europe and in the USA, insulin was used to produce coma for short periods in patients with schizophrenia in an attempt to cure them. Among other uses, was to treat some forms of malnutrition.
So when Donato first learned about insulin’s discovery he formulated an experiment on himself, in search of a cure for his lifelong severe gastrointestinal problems.
In 1926, a non diabetic first injected himself with insulin, proving it was safe and efficient.  After a series of treatments, his symptoms disappeared; he recovered appetite and full health again. The idea was that insulin helped his body tissues assimilate nutrients more efficiently and pondered that could just as well work with medication. Insulin could increase drug concentration potency in the central nervous system, given before various medications, changing the physical and chemical reactions that occurred in the blood, restoring balance and maintaining a state of good health. And it did. In 1930, Dr. Donato successfully treated a patient with neurosyphilis using the name of Cellular Therapy, later known as IPT.


Five years later he applied for U.S. patent of the treatment, where it was granted in 1938. He traveled along the United States demonstrating his medical protocol; at Harvard University, Saint Elizabeth’s Hospital in Washington, D.C., Naval Hospital in San Diego, California and Austin State Hospital in Texas where he treated patients. In Mexico City he opened up a clinic exclusively for IPT. In 1946 the first breast cancer patient was successfully treated.  Many other chronic degenerative illnesses also responded to this innovative breakthrough.
Later on, his son, Dr. Donato Pérez GarcíaBellón (1930-2000) joined his father in the medical field, learning and perfecting the treatment. His clinical research was to measure chemical modifications produced in the blood after the administration of insulin, along with other chemical experiments and international publications that gave IPT full scientific ground. In his research, he concluded that cancer cells have as much as 8 times more insulin receptors in a cancer cell, than that of a normal cell. Together, father and son traveled to Canada, United States and Europe giving a series of conferences to medical societies.

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.